CN103588792B - 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途 - Google Patents

吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途 Download PDF

Info

Publication number
CN103588792B
CN103588792B CN201310068888.8A CN201310068888A CN103588792B CN 103588792 B CN103588792 B CN 103588792B CN 201310068888 A CN201310068888 A CN 201310068888A CN 103588792 B CN103588792 B CN 103588792B
Authority
CN
China
Prior art keywords
oxa
azabicyclo
ring
compound
title compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201310068888.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN103588792A (zh
Inventor
沈竞康
余科
孟韬
马兰萍
萨斯科·奥里耶
孟兰芳
王昕�
陈怡怡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Fudan University
Original Assignee
Shanghai Institute of Materia Medica of CAS
Shandong Luoxin Pharmaceutical Group Co Ltd
Fudan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS, Shandong Luoxin Pharmaceutical Group Co Ltd, Fudan University filed Critical Shanghai Institute of Materia Medica of CAS
Priority to CN201310068888.8A priority Critical patent/CN103588792B/zh
Publication of CN103588792A publication Critical patent/CN103588792A/zh
Priority to DK14760712.1T priority patent/DK2966079T3/da
Priority to RU2015140387A priority patent/RU2662713C2/ru
Priority to ES14760712T priority patent/ES2572105T3/es
Priority to EP14760712.1A priority patent/EP2966079B1/en
Priority to AU2014225155A priority patent/AU2014225155B2/en
Priority to PCT/CN2014/072678 priority patent/WO2014135028A1/zh
Priority to CA2903072A priority patent/CA2903072C/en
Priority to JP2015560533A priority patent/JP2016510042A/ja
Priority to HK16105194.5A priority patent/HK1217197B/en
Priority to DE14760712.1T priority patent/DE14760712T1/de
Priority to US14/842,682 priority patent/US9796732B2/en
Application granted granted Critical
Publication of CN103588792B publication Critical patent/CN103588792B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201310068888.8A 2013-03-04 2013-03-04 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途 Active CN103588792B (zh)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CN201310068888.8A CN103588792B (zh) 2013-03-04 2013-03-04 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途
PCT/CN2014/072678 WO2014135028A1 (zh) 2013-03-04 2014-02-28 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途
JP2015560533A JP2016510042A (ja) 2013-03-04 2014-02-28 ピリドピリミジンまたはピリミドピリミジン系化合物、その製造方法、薬剤組成物及びその用途
ES14760712T ES2572105T3 (es) 2013-03-04 2014-02-28 Compuesto de piridopirimidina o pirimidopirimidina, su método de preparación, su composición farmacéutica y su uso
EP14760712.1A EP2966079B1 (en) 2013-03-04 2014-02-28 Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition and use thereof
AU2014225155A AU2014225155B2 (en) 2013-03-04 2014-02-28 Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition and use thereof
DK14760712.1T DK2966079T3 (da) 2013-03-04 2014-02-28 Pyridopyrimidin eller pyridopyrimidinforbindelse, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf
CA2903072A CA2903072C (en) 2013-03-04 2014-02-28 Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition, and use thereof
RU2015140387A RU2662713C2 (ru) 2013-03-04 2014-02-28 Пиридопиримидиновое соединение, способ получения, фармацевтическая композиция и применение указанных соединений
HK16105194.5A HK1217197B (en) 2013-03-04 2014-02-28 Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition and use thereof
DE14760712.1T DE14760712T1 (de) 2013-03-04 2014-02-28 Pyridopyrimidin- oder Pyrimidopyrimidlnverbindung, Herstellungsverfahren, PharmazeutischeZusammensetzung und Verwendung davon
US14/842,682 US9796732B2 (en) 2013-03-04 2015-09-01 Pyridopyrimidine or pyrimidopyrimidine compound, prepration method, pharmaceutical composition, and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310068888.8A CN103588792B (zh) 2013-03-04 2013-03-04 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途

Publications (2)

Publication Number Publication Date
CN103588792A CN103588792A (zh) 2014-02-19
CN103588792B true CN103588792B (zh) 2016-03-23

Family

ID=50079144

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310068888.8A Active CN103588792B (zh) 2013-03-04 2013-03-04 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途

Country Status (11)

Country Link
US (1) US9796732B2 (https=)
EP (1) EP2966079B1 (https=)
JP (1) JP2016510042A (https=)
CN (1) CN103588792B (https=)
AU (1) AU2014225155B2 (https=)
CA (1) CA2903072C (https=)
DE (1) DE14760712T1 (https=)
DK (1) DK2966079T3 (https=)
ES (1) ES2572105T3 (https=)
RU (1) RU2662713C2 (https=)
WO (1) WO2014135028A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103588792B (zh) 2013-03-04 2016-03-23 中国科学院上海药物研究所 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途
CN106008559B (zh) 2015-03-25 2020-10-16 中国科学院上海药物研究所 取代吡啶并嘧啶类化合物的合成工艺
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CN111148747B (zh) * 2017-11-07 2023-04-04 中国科学院上海药物研究所 吡啶并嘧啶类化合物的盐型和晶型及其制备方法
CN109867667B (zh) * 2017-12-05 2021-06-11 中国药科大学 含有吡啶并嘧啶结构的parp和pi3k双靶点抑制剂
CN113825760B (zh) * 2019-05-06 2022-08-19 南京明德新药研发有限公司 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法
EP4161926A4 (en) * 2020-06-03 2024-06-19 Yumanity Therapeutics, Inc. PYRIDOPYRIMIDINES AND THEIR METHODS OF USE
US20230081426A1 (en) * 2020-09-18 2023-03-16 Plexxikon Inc. Compounds and methods for kras modulation and indications therefor
WO2022228576A1 (zh) * 2021-04-30 2022-11-03 上海医药集团股份有限公司 一种靶向蛋白调节剂的化合物及其应用
WO2023018812A1 (en) * 2021-08-10 2023-02-16 Amgen Inc. Heterocyclic compounds and methods of use
MX2024001894A (es) * 2021-08-10 2024-02-29 Amgen Inc Compuestos heterociclicos y metodos de uso.
EP4540244A1 (en) * 2022-06-15 2025-04-23 Mirati Therapeutics, Inc. Prodrugs of pan-kras inhibitors
WO2024057013A1 (en) * 2022-09-12 2024-03-21 Exscientia Ai Limited Nlrp3 modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006217744A1 (en) * 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited 2,4-diamino-pyridopyrimidine derivatives and their use as MTOR inhibitors
UA96745C2 (en) * 2005-11-22 2011-12-12 Кудос Фармасьютикалз Лимитед PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
DK2050749T3 (en) * 2006-08-08 2018-01-08 Chugai Pharmaceutical Co Ltd PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF
CN101558067B (zh) * 2006-08-23 2014-05-28 库多斯药物有限公司 作为mtor抑制剂的2-甲基吗啉吡啶并、吡唑并和嘧啶并-嘧啶衍生物
US20080233127A1 (en) * 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
WO2010120987A1 (en) * 2009-04-17 2010-10-21 Wyeth Llc Ring fused, ureidoaryl- and carbamoylaryl-bridged morpholino-pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
CN102887895B (zh) * 2011-07-22 2016-08-24 山东轩竹医药科技有限公司 吡啶并嘧啶类mTOR抑制剂
CN102911172A (zh) * 2011-08-04 2013-02-06 上海恒瑞医药有限公司 杂芳基并嘧啶类衍生物、其制备方法和用途
CN103588792B (zh) * 2013-03-04 2016-03-23 中国科学院上海药物研究所 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途

Also Published As

Publication number Publication date
JP2016510042A (ja) 2016-04-04
CA2903072A1 (en) 2014-09-12
US20150368274A1 (en) 2015-12-24
HK1217197A1 (en) 2016-12-30
US9796732B2 (en) 2017-10-24
AU2014225155B2 (en) 2017-11-23
CA2903072C (en) 2019-05-07
AU2014225155A1 (en) 2015-10-15
CN103588792A (zh) 2014-02-19
EP2966079B1 (en) 2021-11-24
WO2014135028A1 (zh) 2014-09-12
EP2966079A1 (en) 2016-01-13
DK2966079T1 (da) 2016-05-17
RU2662713C2 (ru) 2018-07-27
DK2966079T3 (da) 2022-02-14
EP2966079A4 (en) 2016-11-09
RU2015140387A (ru) 2017-03-30
ES2572105T3 (es) 2022-04-13
DE14760712T1 (de) 2017-12-14
ES2572105T1 (es) 2016-05-30

Similar Documents

Publication Publication Date Title
CN103588792B (zh) 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途
JP2022517723A (ja) Ｃｄｋ阻害剤としての大環状化合物、その製造方法及びその医薬品における応用
CN112778275A (zh) 金刚烷基prmt5抑制剂及其应用
WO2020108619A1 (zh) Mnk抑制剂
WO2023030295A1 (zh) 泛素特异性蛋白酶1(usp1)抑制剂
EP2396325B1 (en) Derivatives of azaindoles as inhibitors of protein kinases abl and src
JP2021050231A (ja) 結晶性ｆｇｆｒ４阻害剤化合物およびその使用
JP2023520595A (ja) ピラゾロピリダジノン化合物、その医薬組成物及びその用途
EP2935272A1 (en) Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors
CN115677730B (zh) 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途
CN105153190B (zh) 含联芳基酰胺结构的杂环并嘧啶类化合物及其制备方法和应用
CN108047204A (zh) 2,4-二芳氨基嘧啶衍生物及其制备方法和应用
WO2020156319A1 (zh) N-甲酰胺衍生物、其制备方法及其在医药上的用途
WO2019223777A1 (zh) 一种含有芳胺基取代的吡咯并嘧啶类化合物、制备方法及其应用
WO2022117090A1 (zh) 一种多环化合物及其制备方法和用途
CN104086562A (zh) 含芳腙结构的杂环并嘧啶类化合物的制备及应用
WO2018205916A1 (zh) Fgfr4抑制剂及其制备与应用
CN108484606B (zh) 一种嘧啶并[4,5-f]喹唑啉类化合物及其应用
WO2025087267A1 (zh) 一种含有噻唑基的哌啶并嘧啶类衍生物、其制备方法及其医药上的应用
CN113004282A (zh) 取代的炔基杂环化合物
CN115010711A (zh) 一种蝶啶7（8h）-酮类化合物及其在药学上的应用
JP2022528437A (ja) ピペラジンアミド誘導体、その製造方法及び医薬におけるその用途
CA3136468C (en) Pyrazolopyrazine derived compounds and pharmaceutical compositions used as jak inhibitors
KR101812266B1 (ko) 4-((2-아크릴아미도페닐)아미노)티에노[3,2-d]피리미딘-7-카복스아미드 유도체 및 그의 약학적 활용
HK1217197B (en) Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160204

Address after: 201203 Shanghai City, Pudong New Area Zhangjiang Zuchongzhi Road No. 555

Applicant after: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Applicant after: FUDAN University

Applicant after: SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK Co.,Ltd.

Address before: 201203 Shanghai City, Pudong New Area Zhangjiang Zuchongzhi Road No. 555

Applicant before: Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Applicant before: Fudan University

C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20241018

Address after: 201203 555 Zhangjiang Road, Zhangjiang, Pudong New Area, Shanghai

Patentee after: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Country or region after: China

Patentee after: FUDAN University

Address before: 201203 555 Zhangjiang Road, Zhangjiang, Pudong New Area, Shanghai

Patentee before: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Country or region before: China

Patentee before: FUDAN University

Patentee before: SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK Co.,Ltd.